The anti-MIC mouse IgG2a antibody B1-F2A4 was a provided by Dr T Spies from the Fred Hutchinson Cancer Research Center, Seattle, WA, USA), NIP228 mouse IgG2a isotype control antibody has been previously described (Percival-Alwyn
et al, 2015 (
link)).
The following additional antibodies were used: mouse anti-MICA/B (clone 6D4) (BioLegend, San Diego, CA, USA), rabbit anti-CD63 pAb (ab118307) (Abcam, Cambridge, UK), rabbit anti-CD107a (LAMP1) pAb (#9091) (Cell Signaling, Danvers, MA, USA) and rabbit immunoglobulin fraction isotype control (X0936) (Dako, Ely, UK).
The following secondary conjugated antibodies were used; Rabbit anti-Mouse IgG Alexa488 (A11059) and Goat anti-Rabbit IgG Alexa594 (A11037) (Invitrogen, Thermo Fisher, Basingstoke, UK),
Goat anti-Mouse IgG PE (Jackson Laboratories, Bar Harbor, ME, USA).
Ghadially H., Brown L., Lloyd C., Lewis L., Lewis A., Dillon J., Sainson R., Jovanovic J., Tigue N.J., Bannister D., Bamber L., Valge-Archer V, & Wilkinson R.W. (2017). MHC class I chain-related protein A and B (MICA and MICB) are predominantly expressed intracellularly in tumour and normal tissue. British Journal of Cancer, 116(9), 1208-1217.